Figure 1.
Longitudinal platelet and hemoglobin improvements in patients who received romiplostim after HSCT. (A) CumIs during the study period of platelets counts ≥50 × 109/L (all patients). (B) CumIs of hemoglobin ≥10 g/dL (22 patients at time of first injection). Starting point for analysis is time of study enrollment.

Longitudinal platelet and hemoglobin improvements in patients who received romiplostim after HSCT. (A) CumIs during the study period of platelets counts ≥50 × 109/L (all patients). (B) CumIs of hemoglobin ≥10 g/dL (22 patients at time of first injection). Starting point for analysis is time of study enrollment.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal